Partnership Forum: The purpose of the forum was to identify concerns for high-investment medications related to predictability, affordability, and accessibility. Participants also explored alternative payments, financial tools, and policy initiatives related to these medications.
Health care services provided by pharmacists are a vital part of comprehensive patient care. AMCP supports the use of payment arrangements for pharmacists that include performance-based metrics related to these health care services, on which some of the pharmacist’s reimbursement is based.
AMCP responded in a letter to the editor of Health Affairs stressing that managed care tools work to address the misalignment between drug prices and clinical value. In her latest blog post, AMCP CEO Susan Cantrell dives deeper into the reason behind the response and how it supported the need for value-based pricing.
Traditionally, treatment for chronic conditions addressed symptoms or was disease modifying and required lifelong periodic administration and recurring costs. This research extends a previous study by analyzing member retention for adult patients with certain rare diseases.
A summary of an ICER cost-effectiveness analysis published in JMCP found that despite incremental clinical benefits, biologics used to treat asthma have low long-term value for money.
A systematic review published in JMCP demonstrates that while life expectancy in HIV patients has increased, there is an increased incidence of age- and ART-associated comorbidities. This has important implications for future cost effectiveness analysis.
